Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

Z. S. Pavletic, E. R. Arrowsmith, Philip Jay Bierman, S. A. Goodman, Julie Marie Vose, S. R. Tarantolo, R. S. Stein, Robert G Bociek, J. P. Greer, C. D. Wu, J. P. Kollath, D. D. Weisenburger, A. Kessinger, S. N. Wolff, James Olen Armitage, M. R. Bishop

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/ cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48-88%), 62% (95% CI, 43-88%), and 5% (95%, CI 0-13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect.

Original languageEnglish (US)
Pages (from-to)717-722
Number of pages6
JournalBone marrow transplantation
Volume25
Issue number7
DOIs
StatePublished - Jan 1 2000

Fingerprint

Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Whole-Body Irradiation
Unrelated Donors
Graft vs Host Disease
Cyclophosphamide
Survival
Recurrence
Etoposide
Methotrexate
Cyclosporine
Leukemia
Stem Cells
Survival Rate
Transplantation
Transplants
Drug Therapy
Incidence

Keywords

  • B cell
  • Chronic leukemia
  • Hematopoietic stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. / Pavletic, Z. S.; Arrowsmith, E. R.; Bierman, Philip Jay; Goodman, S. A.; Vose, Julie Marie; Tarantolo, S. R.; Stein, R. S.; Bociek, Robert G; Greer, J. P.; Wu, C. D.; Kollath, J. P.; Weisenburger, D. D.; Kessinger, A.; Wolff, S. N.; Armitage, James Olen; Bishop, M. R.

In: Bone marrow transplantation, Vol. 25, No. 7, 01.01.2000, p. 717-722.

Research output: Contribution to journalArticle

Pavletic, ZS, Arrowsmith, ER, Bierman, PJ, Goodman, SA, Vose, JM, Tarantolo, SR, Stein, RS, Bociek, RG, Greer, JP, Wu, CD, Kollath, JP, Weisenburger, DD, Kessinger, A, Wolff, SN, Armitage, JO & Bishop, MR 2000, 'Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia', Bone marrow transplantation, vol. 25, no. 7, pp. 717-722. https://doi.org/10.1038/sj.bmt.1702237
Pavletic, Z. S. ; Arrowsmith, E. R. ; Bierman, Philip Jay ; Goodman, S. A. ; Vose, Julie Marie ; Tarantolo, S. R. ; Stein, R. S. ; Bociek, Robert G ; Greer, J. P. ; Wu, C. D. ; Kollath, J. P. ; Weisenburger, D. D. ; Kessinger, A. ; Wolff, S. N. ; Armitage, James Olen ; Bishop, M. R. / Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. In: Bone marrow transplantation. 2000 ; Vol. 25, No. 7. pp. 717-722.
@article{9242a36dce9d49f783fa9ee3d61bcbab,
title = "Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia",
abstract = "The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87{\%}) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54{\%}. Fourteen (61{\%}) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39{\%}) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/ cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65{\%} (95{\%} CI, 48-88{\%}), 62{\%} (95{\%} CI, 43-88{\%}), and 5{\%} (95{\%}, CI 0-13{\%}), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect.",
keywords = "B cell, Chronic leukemia, Hematopoietic stem cell transplantation",
author = "Pavletic, {Z. S.} and Arrowsmith, {E. R.} and Bierman, {Philip Jay} and Goodman, {S. A.} and Vose, {Julie Marie} and Tarantolo, {S. R.} and Stein, {R. S.} and Bociek, {Robert G} and Greer, {J. P.} and Wu, {C. D.} and Kollath, {J. P.} and Weisenburger, {D. D.} and A. Kessinger and Wolff, {S. N.} and Armitage, {James Olen} and Bishop, {M. R.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1702237",
language = "English (US)",
volume = "25",
pages = "717--722",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

AU - Pavletic, Z. S.

AU - Arrowsmith, E. R.

AU - Bierman, Philip Jay

AU - Goodman, S. A.

AU - Vose, Julie Marie

AU - Tarantolo, S. R.

AU - Stein, R. S.

AU - Bociek, Robert G

AU - Greer, J. P.

AU - Wu, C. D.

AU - Kollath, J. P.

AU - Weisenburger, D. D.

AU - Kessinger, A.

AU - Wolff, S. N.

AU - Armitage, James Olen

AU - Bishop, M. R.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/ cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48-88%), 62% (95% CI, 43-88%), and 5% (95%, CI 0-13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect.

AB - The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/ cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48-88%), 62% (95% CI, 43-88%), and 5% (95%, CI 0-13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect.

KW - B cell

KW - Chronic leukemia

KW - Hematopoietic stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=19244373520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244373520&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1702237

DO - 10.1038/sj.bmt.1702237

M3 - Article

VL - 25

SP - 717

EP - 722

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -